IPO news | Keen Gene submits application to Hong Kong Stock Exchange

According to the disclosure of the Hong Kong Stock Exchange on December 21, Jiyinjia Technology (Shaoxing) Co., Ltd. (referred to as "Jiyinjia") has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with BOCI and CMBC CAPITAL as its joint sponsors. The prospectus shows that Jiyinjia is a leading precision medicine company in China, deeply embedding AI capabilities into various core links of the biomarker value chain. Based on its independently developed multi-omics platform, combined with basic large models and intelligent AI, the company has built full-chain capabilities from the discovery and validation of multi-omics biomarkers and targets to product development and commercialization. As a result, the company provides three major solutions to hospitals, pharmaceutical and biotechnology companies, medical research institutions, etc.: precision diagnosis, drug development empowerment, and clinical research and transformation.